Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026

Karyopharm Therapeutics (NASDAQ:KPTI [https://seekingalpha.com/symbol/KPTI]) has entered into comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending its cash runway into the second quarter of 2026.

"Following the recent completion of enrollment of our Phase 3 SENTRY trial in myelofibrosis, we are excited to announce this strategic financing which is expected to provide us with the resources needed to deliver top-line data from this pivotal trial," CEO Richard Paulson said [https://seekingalpha.com/pr/20258476-karyopharm-announces-strategic-financing-transactions-to-support-growth-extends-cash-runway] Wednesday.

Each of the financing and capital structure transactions is expected to close on or around October 10.

Karyopharm Therapeutics (NASDAQ:KPTI [https://seekingalpha.com/symbol/KPTI]) shares are up +19.24% pre-market at $6.88.

MORE ON KARYOPHARM THERAPEUTICS

* Karyopharm Therapeutics Inc. 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4812201-karyopharm-therapeutics-inc-2025-q2-results-earnings-call-presentation]
* Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812200-karyopharm-therapeutics-inc-kpti-q2-2025-earnings-call-transcript]
* Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 [https://seekingalpha.com/news/4483297-karyopharm-outlines-1b-peak-u-s-revenue-opportunity-in-myelofibrosis-with-pivotal-phase-iii]
* Seeking Alpha’s Quant Rating on Karyopharm Therapeutics [https://seekingalpha.com/symbol/KPTI/ratings/quant-ratings]
* Historical earnings data for Karyopharm Therapeutics [https://seekingalpha.com/symbol/KPTI/earnings]